Search Tag: DAPA-HF

Cardiology Management

Esccongress-results-from-vanish-and-dapa-hf

2021 27 Aug

At the ESC Congress 2021 today, latest insights into the progression to, and management of, heart failure were presented.   Dr Carolyn Ho of Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA,  discussed the results of the VANISH (Valsartan for Attenuating Disease Evolution in Early Sarcomeric HCM) trial. This trial...Read more

Cardiology Management

Esccongress-preview-dapa-hf-trial

2019 29 Aug

The DAPA-HF trial is the first heart failure outcomes trial with dapagliflozin, an SGLT2 inhibitor, in patients with and without Type-2 diabetes. Findings from the trial will be presented at the ESC Congress next week.  DAPA-HF is an international, multi-centre, parallel-group, randomised, double-blind trial in patients with heart failure...Read more